A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

The purpose of this study is to determine whether MM-093 is safe and effective in the treatment of RA.

Phase 2

Merrimack Pharmaceuticals